Navigation Links
Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
Date:3/19/2009

Launched at the 67th Annual American Academy of Dermatology Meeting

CRANFORD, N.J., March 19 /PRNewswire/ -- Triax Pharmaceuticals, the marketers of Locoid Lipocream(R) (hydrocortisone butyrate 0.1%) the leading mid-potency corticosteroid brand, introduces a new 4 oz. size of its recently launched Locoid(R) Lotion.

Launched at the American Academy of Dermatology (AAD) meeting in San Francisco, Locoid(R) Lotion (hydrocortisone butyrate 0.1%) contains a moisturizing vehicle to cover larger areas and hairy areas of affected skin with an elegant, non-greasy application; and is indicated to treat mild-to-moderate atopic dermatitis in patients as young as 3 months of age(1).

Locoid Lotion (hydrocortisone butyrate 0.1% lotion) is the only class 5 corticosteroid indicated for patients with AD ages 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients(1,2). By the conclusion of one study, 89% of patients had symptoms of skin-barrier disruption eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid Lotion is available nationwide in a 2 fl. oz. or a 4 fl. oz. bottle.

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC

Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States.

(1) Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7:266-271.

(2) Data on file.

www.locoidlotion.com

www.locoid.com


'/>"/>
SOURCE Triax Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potentcy Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
6. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
7. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
8. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
9. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
10. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
11. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ( ... Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people than ... Biggert-Waters Act was enacted to reflect the actual risk in flood zone areas ...
(Date:6/23/2017)... PA (PRWEB) , ... June 23, 2017 , ... ... insurance management, financial planning, and related services to families and business owners in ... a charity drive to benefit senior citizens in the area. , Meals on ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... financial planning to families and business owners in North Central West Virginia, is ... provide services to differently abled residents in the region. , The Stepping Stones ...
(Date:6/22/2017)... ... , ... Plastic Surgery Associates is proud to report that founding surgeon, Francisco ... and information firm, Castle Connolly, releases their list of the most notable and trusted ... time that Dr. Canales has been recognized by Castle Connolly. , ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
(Date:6/5/2017)... , June 5, 2017 The Cincinnati ... of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... Enquirer . Results are based on an employee ... organizational health and workplace improvement. The survey measures several aspects ... ...
Breaking Medicine Technology: